Related Experiment Video

Updated: Jun 3, 2026

Isolation of Primary Cancer-Associated Fibroblasts from a Syngeneic Murine Model of Breast Cancer for the Study of Targeted Nanoparticles
08:02

Isolation of Primary Cancer-Associated Fibroblasts from a Syngeneic Murine Model of Breast Cancer for the Study of Targeted Nanoparticles

Published on: May 14, 2021

Targeting fibroblast-growth-factor-receptor-dependent signaling for cancer therapy

Christine Heinzle1, Hedwig Sutterlüty, Michael Grusch

  • 1Medical University Vienna, Institute of Cancer Research, Department of Medicine 1, Vienna,Austria.

Expert Opinion on Therapeutic Targets
|March 8, 2011
PubMed
Abstract

Insights

Fibroblast growth factors (FGF) and their receptors (FGFRs) are key in cancer development. Targeting FGF signaling is a promising cancer therapy strategy, but requires careful consideration of side effects and further research into biomarkers.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Therapeutics

Background:

  • Fibroblast growth factors (FGF) signaling pathways are implicated in four major hallmarks of cancer.
  • FGF-dependent signaling has become a central focus in cancer therapy research over the last decade.
  • Numerous publications highlight the significance of FGF signaling in oncogenesis.

Purpose of the Study:

  • To outline the physiological functions of FGF signaling.
  • To explain how deregulated FGFs and FGFRs contribute to cancer.
  • To summarize the current landscape of therapeutic targeting for FGFR in cancer.

Main Methods:

  • Review of existing literature on FGF signaling in cancer.
  • Analysis of ongoing research from the authors' groups.
  • Description of the biological effects of deregulated FGFR signaling in malignancies.

Main Results:

  • Deregulated FGF and FGFR signaling drives oncogenic effects through their physiological roles.
  • Current therapeutic strategies targeting FGFR are summarized.
  • The biological impact of aberrant FGFR signaling in various cancers is detailed.

Conclusions:

  • Targeting FGFR signaling presents a promising avenue for cancer therapy.
  • Therapeutic strategies must be carefully designed, considering the physiological roles of FGF signaling.
  • Preventive measures against FGF-related side effects may be necessary.
  • Combination therapies and further investigation of FGF-related biomarkers are crucial for optimizing treatment outcomes.

More Related Videos

Screening and Identification of Small Peptides Targeting Fibroblast Growth Factor Receptor2 using a Phage Display Peptide Library07:32

Screening and Identification of Small Peptides Targeting Fibroblast Growth Factor Receptor2 using a Phage Display Peptide Library

Published on: September 30, 2019

A Mouse Model to Investigate the Role of Cancer-Associated Fibroblasts in Tumor Growth06:35

A Mouse Model to Investigate the Role of Cancer-Associated Fibroblasts in Tumor Growth

Published on: December 22, 2020

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
TGF - β Signaling Pathway01:16

TGF - β Signaling Pathway

The TGF-β signaling pathway regulates cell growth, differentiation, adhesion, motility, and development. TGF-β ligands that induce TGF-β signaling are synthesized in their latent form. Several proteases or cell surface receptors such as integrins act upon the latent form, releasing the active ligand. There are three types of mammalian TGF-βs: (TGF-β1, TGF-β2, and TGF-β3) that bind as homodimers or heterodimers to TGF-β receptors. The TGF-β receptors are of three kinds RI, RII, and RIII. The RI...